Cero Therapeutics Holdings Inc (CERO)

$1.91 -0.09 (-4.50%)
Market Cap 2.41M
Revenue (ttm) 0.00
Net Income (ttm) -8.30M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 593,000
Avg Vol 308,180
Day's Range N/A - N/A
Shares Out 1.21M
Stochastic %K 5%
Beta 0.41
Analysts Strong Sell
Price Target $22.50

Company Profile

CERo Therapeutics Holdings, Inc., an immunotherapy company, focuses on advancing the development of engineered T cell therapeutics for the treatment of cancer. Its lead development candidate is CER-1236, an autologous T cell therapy candidate for the treatment of hematologic malignancies and solid tumors. The company was incorporated in 2021 and is based in South San Francisco, California.

Industry: Biotechnology
Sector: Healthcare
Phone: (650) 407-2376
Address:
201 Haskins Way, Suite 230, South San Francisco, United States
Tough_Shit
Tough_Shit Oct. 25 at 1:39 AM
$CERO this is fake
2 · Reply
Zerodegree00
Zerodegree00 Oct. 25 at 12:42 AM
$CERO I lost 😡 everything here 😞😞😞
1 · Reply
Zerodegree00
Zerodegree00 Oct. 25 at 12:41 AM
$CERO Bankruptcy very soon , OMG 100% Bearish
1 · Reply
BPler
BPler Oct. 24 at 7:35 PM
$CERO https://www.quiverquant.com/news/CERo+Therapeutics+Completes+First+Tranche+of+%247+Million+Financing+to+Support+Clinical+Development+and+Nasdaq+Compliance Well money received, so should be compliant again
0 · Reply
Watz
Watz Oct. 24 at 7:09 PM
$CERO bottom?
1 · Reply
Caputxino
Caputxino Oct. 24 at 6:10 PM
$CERO looks like institutional movement here... is there a partnership being cooked?
0 · Reply
aafetygod
aafetygod Oct. 24 at 6:07 PM
$CERO 12 run coming soon.
0 · Reply
zeph1985
zeph1985 Oct. 24 at 4:40 PM
$CERO are they still diluteing?
1 · Reply
Caputxino
Caputxino Oct. 24 at 4:36 PM
$CERO there's big buy orders coming in
2 · Reply
Ceri78
Ceri78 Oct. 24 at 4:08 PM
$CERO I wish their medicine will be useful for company management! Assholes! Stay away from this robbers!
1 · Reply
Latest News on CERO
CERo Therapeutics Announces Third Dose for Patient in Phase 1 Clinical Trial of CER-1236 in AML

Oct 21, 2025, 8:15 AM EDT - 4 days ago

CERo Therapeutics Announces Third Dose for Patient in Phase 1 Clinical Trial of CER-1236 in AML

CERo Therapeutics to Participate in Stem Cell Therapy Panel at the Maxim Growth Summit 2025

Oct 15, 2025, 8:30 AM EDT - 10 days ago

CERo Therapeutics to Participate in Stem Cell Therapy Panel at the Maxim Growth Summit 2025

CERo Therapeutics Announces Completion of First Cohort of Phase 1 Clinical Trial of CER-1236 in AML

Oct 13, 2025, 8:30 AM EDT - 12 days ago

CERo Therapeutics Announces Completion of First Cohort of Phase 1 Clinical Trial of CER-1236 in AML

CERo Therapeutics Progresses Phase 1 CER-1236 AML Trial with Dosing of Third Patient in Initial Dose Cohort

Sep 22, 2025, 9:15 AM EDT - 4 weeks ago

CERo Therapeutics Progresses Phase 1 CER-1236 AML Trial with Dosing of Third Patient in Initial Dose Cohort

Top 3 Health Care Stocks You'll Regret Missing In Q3

Sep 9, 2025, 9:12 AM EDT - 6 weeks ago

Top 3 Health Care Stocks You'll Regret Missing In Q3

SMMT LNAI

CERo Therapeutics Receives Notice of Allowance from U.S. Patent and Trade Office on Composition of Matter and Method of Use for CER-1236 in Cancer with Expected Protection Through 2041

Sep 9, 2025, 8:15 AM EDT - 6 weeks ago

CERo Therapeutics Receives Notice of Allowance from U.S. Patent and Trade Office on Composition of Matter and Method of Use for CER-1236 in Cancer with Expected Protection Through 2041

CERo Therapeutics Announces Dose Intensification in Phase 1 Study of CER-1236 in Acute Myeloid Leukemia

Sep 8, 2025, 8:45 AM EDT - 6 weeks ago

CERo Therapeutics Announces Dose Intensification in Phase 1 Study of CER-1236 in Acute Myeloid Leukemia

CERo Therapeutics Receives FDA Fast Track Designation for CER-1236 in Acute Myeloid Leukemia (AML)

Sep 5, 2025, 8:00 AM EDT - 7 weeks ago

CERo Therapeutics Receives FDA Fast Track Designation for CER-1236 in Acute Myeloid Leukemia (AML)

CERo Therapeutics Doses Second Acute Myeloid Leukemia Patient with CER-1236

Jul 31, 2025, 8:10 AM EDT - 3 months ago

CERo Therapeutics Doses Second Acute Myeloid Leukemia Patient with CER-1236

Invivoscribe Expands Flow Cytometry Services to Accelerate CAR-T Immunotherapy Development and Regulatory Readiness with the Initiation of CERo Therapeutics Phase 1 Clinical Trial

Jul 8, 2025, 12:00 AM EDT - 3 months ago

Invivoscribe Expands Flow Cytometry Services to Accelerate CAR-T Immunotherapy Development and Regulatory Readiness with the Initiation of CERo Therapeutics Phase 1 Clinical Trial

CERo Therapeutics Holdings, Inc. Announces First Patient Completes Dose-Limiting Toxicity Observation Period with No Reported DLTs in Phase 1 Trial of CER-1236

Jun 23, 2025, 8:15 AM EDT - 4 months ago

CERo Therapeutics Holdings, Inc. Announces First Patient Completes Dose-Limiting Toxicity Observation Period with No Reported DLTs in Phase 1 Trial of CER-1236

CERo Therapeutics Holdings, Inc. Announces FDA Orphan Drug Designation Granted to CER-1236 for the Treatment of Acute Myeloid Leukemia (AML)

Jun 17, 2025, 8:15 AM EDT - 4 months ago

CERo Therapeutics Holdings, Inc. Announces FDA Orphan Drug Designation Granted to CER-1236 for the Treatment of Acute Myeloid Leukemia (AML)

CERo Therapeutics Holdings, Inc. Announces Reverse Stock Split

Jun 11, 2025, 9:10 AM EDT - 4 months ago

CERo Therapeutics Holdings, Inc. Announces Reverse Stock Split

CERo Therapeutics, Inc. Announces Option Exercise for Additional Series D Financing

Jun 6, 2025, 8:15 AM EDT - 5 months ago

CERo Therapeutics, Inc. Announces Option Exercise for Additional Series D Financing

CERo Therapeutics Holdings, Inc. Announces Continued Enhancement of Intellectual Property Portfolio with Two Granted U.S. Patents and European Patent Application Allowance Regarding Company's Lead Compound CER-1236

Jun 2, 2025, 9:05 AM EDT - 5 months ago

CERo Therapeutics Holdings, Inc. Announces Continued Enhancement of Intellectual Property Portfolio with Two Granted U.S. Patents and European Patent Application Allowance Regarding Company's Lead Compound CER-1236

CERo Therapeutics Holdings, Inc. Doses First Patient with CER-1236 in Phase 1 Clinical Trial for Acute Myeloid Leukemia and is Advancing Through Protocol-Defined Evaluations

May 30, 2025, 8:15 AM EDT - 5 months ago

CERo Therapeutics Holdings, Inc. Doses First Patient with CER-1236 in Phase 1 Clinical Trial for Acute Myeloid Leukemia and is Advancing Through Protocol-Defined Evaluations

CERo Therapeutics Holdings, Inc. Regains Compliance with Nasdaq Listing Rule 5550(b)(1)

May 8, 2025, 8:15 AM EDT - 6 months ago

CERo Therapeutics Holdings, Inc. Regains Compliance with Nasdaq Listing Rule 5550(b)(1)

CERo Therapeutics Holdings, Inc. Announces TriStar Centennial Medical Center as a Clinical Trial Site for its Phase 1 Clinical Trial of CER-1236 in Acute Myeloid Leukemia

Apr 30, 2025, 8:15 AM EDT - 6 months ago

CERo Therapeutics Holdings, Inc. Announces TriStar Centennial Medical Center as a Clinical Trial Site for its Phase 1 Clinical Trial of CER-1236 in Acute Myeloid Leukemia

CERo Therapeutics Holdings, Inc. to Present Poster on Lead Program, CER-1236, at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting

Apr 25, 2025, 8:15 AM EDT - 6 months ago

CERo Therapeutics Holdings, Inc. to Present Poster on Lead Program, CER-1236, at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting

CERo Therapeutics Holdings, Inc. Announces Sarah Cannon Research Institute at Colorado Blood Cancer Institute as Key Clinical Trial Site for its Phase 1 Clinical Trial of CER-1236 in Acute Myeloid Leukemia

Apr 24, 2025, 8:15 AM EDT - 6 months ago

CERo Therapeutics Holdings, Inc. Announces Sarah Cannon Research Institute at Colorado Blood Cancer Institute as Key Clinical Trial Site for its Phase 1 Clinical Trial of CER-1236 in Acute Myeloid Leukemia

CERo Therapeutics, Inc. Announces Up to $8 Million Series D Financing

Apr 22, 2025, 8:15 AM EDT - 6 months ago

CERo Therapeutics, Inc. Announces Up to $8 Million Series D Financing

CERo Therapeutics Holdings, Inc. Announces Critical Patent Application Allowances from the U.S. Patent Office Covering Company's Lead Compound CER-1236

Apr 10, 2025, 8:15 AM EDT - 7 months ago

CERo Therapeutics Holdings, Inc. Announces Critical Patent Application Allowances from the U.S. Patent Office Covering Company's Lead Compound CER-1236

CERo Therapeutics Holdings, Inc. Announces Initial Clinical Trial Site for its Phase 1 Clinical Trial of CER-1236 in Acute Myeloid Leukemia

Apr 9, 2025, 8:15 AM EDT - 7 months ago

CERo Therapeutics Holdings, Inc. Announces Initial Clinical Trial Site for its Phase 1 Clinical Trial of CER-1236 in Acute Myeloid Leukemia

CERo Therapeutics Holdings, Inc. Receives FDA Clearance of Second Investigational New Drug Application to Initiate Phase 1 Clinical Trial of Lead Compound CER-1236 in Solid Tumors

Mar 31, 2025, 8:15 AM EDT - 7 months ago

CERo Therapeutics Holdings, Inc. Receives FDA Clearance of Second Investigational New Drug Application to Initiate Phase 1 Clinical Trial of Lead Compound CER-1236 in Solid Tumors

CERo Therapeutics Holdings, Inc. Poised to Initiate Enrollment of Phase 1 Trial of CER-1236 in AML Following Positive FDA Review of Manufacturing

Mar 27, 2025, 8:15 AM EDT - 7 months ago

CERo Therapeutics Holdings, Inc. Poised to Initiate Enrollment of Phase 1 Trial of CER-1236 in AML Following Positive FDA Review of Manufacturing

CERo Therapeutics Holdings, Inc. Continues to Progress Toward Initial Dosing of Patients in Phase 1 Trial with Agreement with University of California Davis for Manufacturing Services

Mar 19, 2025, 8:15 AM EDT - 7 months ago

CERo Therapeutics Holdings, Inc. Continues to Progress Toward Initial Dosing of Patients in Phase 1 Trial with Agreement with University of California Davis for Manufacturing Services

CERo Therapeutics Holdings, Inc. Presents Encouraging Preclinical Data Demonstrating CER-1236 May be Targeted to Ovarian Cancer Cells Without Toxicities at 2025 SITC Spring Scientific Cellular Therapy for Solid Tumors Meeting

Mar 13, 2025, 8:15 AM EDT - 8 months ago

CERo Therapeutics Holdings, Inc. Presents Encouraging Preclinical Data Demonstrating CER-1236 May be Targeted to Ovarian Cancer Cells Without Toxicities at 2025 SITC Spring Scientific Cellular Therapy for Solid Tumors Meeting

CERo Therapeutics Holdings, Inc. Announces Progress in Initiation of Phase 1 Clinical Trial by Executing an Agreement with Contract Research Organization CellCarta to Manage Translational Assays

Mar 6, 2025, 8:15 AM EST - 8 months ago

CERo Therapeutics Holdings, Inc. Announces Progress in Initiation of Phase 1 Clinical Trial by Executing an Agreement with Contract Research Organization CellCarta to Manage Translational Assays

CERo Therapeutics Holdings, Inc. to Present Data at the Society for Immunotherapy of Cancer Spring Scientific March 12-14

Mar 5, 2025, 8:15 AM EST - 8 months ago

CERo Therapeutics Holdings, Inc. to Present Data at the Society for Immunotherapy of Cancer Spring Scientific March 12-14

CERo Therapeutics Holdings, Inc. Highlights Progress

Feb 6, 2025, 8:15 AM EST - 9 months ago

CERo Therapeutics Holdings, Inc. Highlights Progress

CERo Therapeutics Announces $5 Million Public Offering Priced At-The-Market Under Nasdaq Rules

Feb 5, 2025, 8:00 PM EST - 9 months ago

CERo Therapeutics Announces $5 Million Public Offering Priced At-The-Market Under Nasdaq Rules

CERo Therapeutics, Inc. Appoints Chris Ehrlich CEO

Dec 6, 2024, 9:00 AM EST - 11 months ago

CERo Therapeutics, Inc. Appoints Chris Ehrlich CEO

CERo Therapeutics, Inc. Receives FDA Clearance of Investigational New Drug Application to Initiate Phase 1 Clinical Trial of Its Lead Compound CER-1236 in Acute Myelogenous Leukemia

Nov 15, 2024, 8:45 AM EST - 1 year ago

CERo Therapeutics, Inc. Receives FDA Clearance of Investigational New Drug Application to Initiate Phase 1 Clinical Trial of Its Lead Compound CER-1236 in Acute Myelogenous Leukemia

CERo Therapeutics, Inc. Presents Preclinical Data Demonstrating CER-1236 Killing Ovarian Cancer Cell Lines Without Toxicity

Nov 11, 2024, 8:15 AM EST - 1 year ago

CERo Therapeutics, Inc. Presents Preclinical Data Demonstrating CER-1236 Killing Ovarian Cancer Cell Lines Without Toxicity

CERo Therapeutics, Inc. Provides Corporate Update

Oct 21, 2024, 9:00 AM EDT - 1 year ago

CERo Therapeutics, Inc. Provides Corporate Update

CERo Therapeutics, Inc. Names Al Kucharchuk Chief Financial Officer and Kristen Pierce Chief Development Officer

Oct 2, 2024, 9:15 AM EDT - 1 year ago

CERo Therapeutics, Inc. Names Al Kucharchuk Chief Financial Officer and Kristen Pierce Chief Development Officer

Dow Tumbles Over 200 Points; CERo Therapeutics Shares Jump

Sep 25, 2024, 2:49 PM EDT - 1 year ago

Dow Tumbles Over 200 Points; CERo Therapeutics Shares Jump

CERo Therapeutics, Inc. Announces Financing and Provides Update on Investigational New Drug Application for CER-1236

Sep 25, 2024, 9:17 AM EDT - 1 year ago

CERo Therapeutics, Inc. Announces Financing and Provides Update on Investigational New Drug Application for CER-1236

Top 3 Health Care Stocks Which Could Rescue Your Portfolio In July

Jul 18, 2024, 7:55 AM EDT - 1 year ago

Top 3 Health Care Stocks Which Could Rescue Your Portfolio In July

ASLN

CERo Therapeutics, Inc. Completes IND-Enabling Activities Following Successful Manufacturing Runs for Lead Compound CER-1236

Jun 13, 2024, 8:15 AM EDT - 1 year ago

CERo Therapeutics, Inc. Completes IND-Enabling Activities Following Successful Manufacturing Runs for Lead Compound CER-1236

CERo Therapeutics, Inc. Provides Corporate Update for Shareholders

May 15, 2024, 8:00 AM EDT - 1 year ago

CERo Therapeutics, Inc. Provides Corporate Update for Shareholders

CERo Therapeutics, Inc. Announces Publication of Preclinical Research Supporting the Use of Its Clinical Candidate CER-1236 to Treat AML Patients

Mar 7, 2024, 7:00 AM EST - 1 year ago

CERo Therapeutics, Inc. Announces Publication of Preclinical Research Supporting the Use of Its Clinical Candidate CER-1236 to Treat AML Patients

Phoenix Biotech Acquisition Corp. and CERo Therapeutics, Inc. Announce Close of Business Combination

Feb 14, 2024, 4:48 PM EST - 1 year ago

Phoenix Biotech Acquisition Corp. and CERo Therapeutics, Inc. Announce Close of Business Combination

CERo Therapeutics, Inc. and Phoenix Biotech Acquisition Corp. Announce Merger Agreement to Create Public Company Advancing the Development of Next Generation Engineered T Cell Therapeutics

Jun 5, 2023, 8:00 AM EDT - 2 years ago

CERo Therapeutics, Inc. and Phoenix Biotech Acquisition Corp. Announce Merger Agreement to Create Public Company Advancing the Development of Next Generation Engineered T Cell Therapeutics

Intrinsic Medicine and Phoenix Biotech Acquisition Corp. Mutually Agree to Terminate Business Combination Agreement

Dec 6, 2022, 9:18 PM EST - 3 years ago

Intrinsic Medicine and Phoenix Biotech Acquisition Corp. Mutually Agree to Terminate Business Combination Agreement

Intrinsic Medicine and Phoenix Biotech Acquisition Corp. Announce Merger Agreement to Create Public Company Leveraging Human Milk Biology to Treat Gut-Brain Axis Disorders

Oct 31, 2022, 8:00 AM EDT - 3 years ago

Intrinsic Medicine and Phoenix Biotech Acquisition Corp. Announce Merger Agreement to Create Public Company Leveraging Human Milk Biology to Treat Gut-Brain Axis Disorders

Tough_Shit
Tough_Shit Oct. 25 at 1:39 AM
$CERO this is fake
2 · Reply
Zerodegree00
Zerodegree00 Oct. 25 at 12:42 AM
$CERO I lost 😡 everything here 😞😞😞
1 · Reply
Zerodegree00
Zerodegree00 Oct. 25 at 12:41 AM
$CERO Bankruptcy very soon , OMG 100% Bearish
1 · Reply
BPler
BPler Oct. 24 at 7:35 PM
$CERO https://www.quiverquant.com/news/CERo+Therapeutics+Completes+First+Tranche+of+%247+Million+Financing+to+Support+Clinical+Development+and+Nasdaq+Compliance Well money received, so should be compliant again
0 · Reply
Watz
Watz Oct. 24 at 7:09 PM
$CERO bottom?
1 · Reply
Caputxino
Caputxino Oct. 24 at 6:10 PM
$CERO looks like institutional movement here... is there a partnership being cooked?
0 · Reply
aafetygod
aafetygod Oct. 24 at 6:07 PM
$CERO 12 run coming soon.
0 · Reply
zeph1985
zeph1985 Oct. 24 at 4:40 PM
$CERO are they still diluteing?
1 · Reply
Caputxino
Caputxino Oct. 24 at 4:36 PM
$CERO there's big buy orders coming in
2 · Reply
Ceri78
Ceri78 Oct. 24 at 4:08 PM
$CERO I wish their medicine will be useful for company management! Assholes! Stay away from this robbers!
1 · Reply
Caputxino
Caputxino Oct. 24 at 3:54 PM
$CERO added 10k at 1.9.. holding 50k
0 · Reply
Scamstock
Scamstock Oct. 24 at 3:44 PM
$CERO patience let it Come to you - will make First entry around 1.75 ish based off filings IMO
0 · Reply
Zerodegree00
Zerodegree00 Oct. 24 at 3:33 PM
$CERO Another R/S Coming, End of the price would be $1.49 😡😡😡
0 · Reply
Zerodegree00
Zerodegree00 Oct. 24 at 3:29 PM
$CERO f…..u CERo scammer m…..f
0 · Reply
StockGoing
StockGoing Oct. 24 at 2:21 PM
$VIVK $CERO $ASST $VERU 🔥🔥🔥
0 · Reply
PrimeTradingCorp
PrimeTradingCorp Oct. 24 at 10:58 AM
$AREB and $CERO trades huge wins this week. Caught the oil spike too. Now adding some $PAVS on this dip. Still watching $BCG to rebuy when settled. GLTA
0 · Reply
MichaelOb
MichaelOb Oct. 24 at 4:17 AM
$CERO this needs $110 to break even for my portfolio
0 · Reply
zeph1985
zeph1985 Oct. 23 at 9:29 PM
$CERO who bought gor 600k dollar?
1 · Reply
aafetygod
aafetygod Oct. 23 at 9:05 PM
$CERO This stock could rise to a minimum of $7, with a median target of $12, and a maximum of $18. Personally, I'm targeting $18.
0 · Reply
Caputxino
Caputxino Oct. 23 at 9:03 PM
$CERO WHATwhere those two 142.5k transactions
0 · Reply
BPler
BPler Oct. 23 at 4:22 PM
$CERO Investor relations in parent leave or why are we so shy?
0 · Reply
Ceri78
Ceri78 Oct. 23 at 2:07 PM
$CERO Steady down until next RS, stay away
0 · Reply